BCRB 2018

19/09/2018

Tumor vasculature as a target

• Angiogenesis inhibiting agents • Target angiogenesis process

• Vascular disrupting agents • Damage tumor blood vessels • Affect blood flow

35

Bevacizumab • Chimeric monoclonal antibody that targets VEGF

18